Mazdutide vs Retatrutide: Dual-Agonist vs Triple-Agonist, Head to Head

Two incretin-based obesity drugs are redefining what pharmacological weight loss looks like, but they do it with different receptor arithmetic. Mazdutide — developed by Innovent Biologics and approved in China in 2025 under the brand name Xinerui — is a GLP-1/glucagon dual agonist. Retatrutide, from Eli Lilly, is a GLP-1/GIP/glucagon triple agonist still in Phase 3. In their respective Phase 2–3 obesity trials, mazdutide 9 mg produced about 15% body-weight reduction at 48 weeks (GLORY-1 program), while retatrutide 12 mg produced about 24% at 48 weeks in a US obesity cohort. This article unpacks the mechanism, trial data, and population context behind that gap.

Key Takeaways

• Mazdutide is a dual agonist at GLP-1 and glucagon receptors — no GIP activity.
• Retatrutide is a triple agonist at GLP-1, GIP, and glucagon receptors.
• Approved status differs sharply — mazdutide is approved in China for obesity (2025); retatrutide is still investigational globally.
• Peak Phase 2–3 weight loss — mazdutide ~15% at 48 weeks (9 mg); retatrutide ~24% at 48 weeks (12 mg).
• Population context matters — mazdutide trials were in Chinese obesity cohorts (lower baseline BMI); retatrutide trials in US cohorts (higher baseline BMI).
• The GIP question is central — retatrutide's additional GIP activity is believed to amplify weight loss and may improve tolerability, but no head-to-head trial has tested this directly.

Mechanism: dual vs triple agonism

GLP-1 agonism drives satiety, slows gastric emptying, and improves insulin sensitivity. Glucagon agonism, at the right receptor balance, increases energy expenditure, promotes hepatic lipid oxidation, and reduces liver fat. GIP agonism, in the Lilly design philosophy, appears to amplify GLP-1 effects on weight loss while buffering nausea.

Mazdutide chooses the dual path — GLP-1 for satiety and glycemic control, glucagon for energy expenditure. It leaves GIP off the table. Retatrutide stacks all three. In theory, the triple agonist captures everything the dual does plus the GIP amplifier, which is consistent with the larger weight-loss numbers reported in Phase 2 — but mechanism alone does not prove superiority in head-to-head terms.

Table 1 — Mechanism, dose, trial outcomes, and status

Trial data: what each program has shown

The mazdutide GLORY-1 program evaluated weekly mazdutide in Chinese adults with obesity, with a mean baseline BMI around 32 kg/m² in reported cohorts. At 48 weeks, mean body-weight reductions of ~11% (6 mg) and ~15% (9 mg) were reported, with sizeable placebo-adjusted differences and improvements in waist circumference, liver fat, and triglycerides. Mazdutide 6 mg has been described as comparable in magnitude to semaglutide 2.4 mg in some comparative framings, though not in a direct head-to-head.

The retatrutide Phase 2 trial (Jastreboff et al., NEJM 2023) randomised US adults with obesity (mean BMI ~37 kg/m²) to placebo, 1 mg, 4 mg, 8 mg, or 12 mg weekly for 48 weeks. Mean weight reductions were ~7% (1 mg), ~13% (4 mg), ~17–19% (8 mg), and ~24% (12 mg) versus ~2% placebo. The 24% number is the single highest weight loss published to date for any obesity drug trial of this length.

Table 2 — Weight-loss trajectory: GLORY-1 and Phase 2 retatrutide

Figures are summarised from published trial reports and congress presentations and should be read as approximate. Cross-trial comparison is inherently weak because baseline BMI, population genetics, titration schedules, and run-in design differ.

Population and context: why direct comparison is hard

The GLORY-1 mazdutide program enrolled Chinese adults with obesity, with lower mean baseline BMI than the US SURMOUNT and TRIUMPH cohorts. Lower baseline BMI tends to compress the achievable percentage weight loss on any obesity drug, both because less total adipose is available to lose and because responders at lower BMIs tend to reach new homeostatic set points sooner.

Retatrutide trials have been in populations with higher baseline BMI (~37 kg/m² mean) and have more adipose runway. Any attempt to say "retatrutide beats mazdutide by 9 percentage points" has to be deflated by population context. A fair reading is that the triple-agonist arithmetic probably does add weight-loss capacity relative to dual GLP-1/glucagon — but the magnitude is almost certainly smaller than the raw trial numbers suggest.

Side effects, tolerability, and metabolic markers

Both compounds show the familiar incretin-class adverse-event spectrum: nausea, vomiting, diarrhea, and constipation dominate, peaking during dose escalation and attenuating with time. Mazdutide trials have reported acceptable tolerability profiles with discontinuation rates in a range comparable to other GLP-1-class drugs. Retatrutide at 8–12 mg shows GI incidence that scales with dose and includes the alopecia signal discussed in a separate article.

Metabolic markers tracked in both programs — HbA1c in those with type 2 diabetes, liver fat, triglycerides, blood pressure — have moved favourably. Mazdutide has particular emphasis on liver fat reduction given the glucagon component; retatrutide Phase 2 also showed meaningful hepatic signal.

Approval and access

Mazdutide was approved in China in 2025 for obesity under the brand name Xinerui, following GLORY-1 readouts. Regional expansion across Asia-Pacific is in progress. Mazdutide is not available in the US pharmaceutical channel. Retatrutide remains investigational globally, with the TRIUMPH Phase 3 program ongoing. US FDA submission is anticipated in the 2026–2027 window pending full trial readouts.

For practical purposes, this means neither compound is routinely available by prescription outside their respective jurisdictions in standard pharmacy channels. Both have active research-chemical presences, with the same purity, sterility, and legal caveats that apply to any investigational peptide.

Does the dual-vs-triple distinction actually matter?

From a mechanistic standpoint, yes — the inclusion of GIP in retatrutide gives it an additional lever that mazdutide does not have, and the Lilly tirzepatide program established that GIP contributes materially to weight loss. From a clinical outcomes standpoint, the honest answer is: probably, but by less than the headline numbers suggest, and we will not know for sure until a head-to-head trial runs or the Phase 3 data for both programs matures.

The broader point is that the dual- and triple-agonist thesis is now validated. Both molecules show that going beyond GLP-1 monotherapy delivers more weight loss. The debate between mazdutide-style dual and retatrutide-style triple is a debate about receptor combinations, not whether multi-receptor agonism works.

Conclusion

Mazdutide and retatrutide represent two parallel bets on the future of obesity pharmacology. Mazdutide — approved in China, available by prescription in that market — offers a dual GLP-1/glucagon pathway with Phase 3-grade data showing ~15% weight loss at 9 mg. Retatrutide — still investigational — adds GIP and shows ~24% weight loss at 12 mg in Phase 2, though the comparison deflates meaningfully once baseline BMI and population differences are accounted for.

For most readers, the practical takeaway is that both drugs validate the multi-agonist thesis and that regulatory timing, geography, and sourcing — not pure mechanism — will determine which molecule they ever actually access. The next 24 months of trial readouts and regulatory decisions will clarify how much of the apparent gap survives direct comparison.

Frequently Asked Questions

Sources

Research disclaimer: This article is prepared by the Peptides Hive Research Desk and summarises publicly available trial information for educational purposes. Mazdutide is not approved in the US; retatrutide is investigational. Nothing here is medical advice, prescribing guidance, or an endorsement of any sourcing channel. Discuss any obesity pharmacology decisions with a qualified clinician.